Charles River Laboratories International (NYSE:CRL) Upgraded by Baird R W to Strong-Buy Rating

Baird R W upgraded shares of Charles River Laboratories International (NYSE:CRL) from a hold rating to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

Several other equities analysts have also recently weighed in on the stock. Citigroup raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and raised their target price for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research report on Monday, October 6th. JPMorgan Chase & Co. boosted their price objective on shares of Charles River Laboratories International from $160.00 to $165.00 and gave the stock a “neutral” rating in a research note on Thursday. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. Finally, Barclays boosted their price target on Charles River Laboratories International from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $186.93.

Charles River Laboratories International Stock Up 1.9%

Charles River Laboratories International stock opened at $170.82 on Thursday. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $222.10. The company has a fifty day simple moving average of $167.91 and a 200 day simple moving average of $154.56. The company has a market cap of $8.41 billion, a P/E ratio of -128.44, a price-to-earnings-growth ratio of 4.83 and a beta of 1.53.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company’s quarterly revenue was down .5% on a year-over-year basis. During the same period in the prior year, the business posted $2.59 EPS. Research analysts anticipate that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the completion of the sale, the executive vice president owned 24,116 shares of the company’s stock, valued at $3,800,681.60. The trade was a 3.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group boosted its stake in shares of Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after buying an additional 86 shares during the period. Cromwell Holdings LLC lifted its position in shares of Charles River Laboratories International by 542.9% during the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 152 shares during the period. Neo Ivy Capital Management bought a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at $29,000. Atlantic Union Bankshares Corp acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter worth $31,000. Finally, Geneos Wealth Management Inc. increased its position in shares of Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after purchasing an additional 145 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).